#VisualAbstract Addition of daratumumab to standard of care improves minimal residual disease negativity in patients with newly diagnosed, transplant-ineligible multiple myeloma byKathleen Lau July 23, 2021 0
#VisualAbstract Obesity and body weight was not correlated with survival outcomes in patients with relapsed/refractory large B-cell lymphoma treated with CAR T-Cell therapy byKathleen Lau July 11, 2021 0
#VisualAbstract Ibrutinib may be beneficial in heavily pretreated patients with classic and variant hairy cell leukemia byKathleen Lau July 8, 2021 0
#VisualAbstract Idecabtagene vicleucel demonstrates higher efficacy over currently available therapies in triple-class relapsed and refractory multiple myeloma byKathleen Lau July 1, 2021 0
#VisualAbstract Post-transplant cyclophosphamide is associated with increased incidence of cytomegalovirus infection in hematopoietic cell transplant recipients byKathleen Lau June 25, 2021 0
#VisualAbstract Changes in minimal residual disease status is associated with risk of disease progression in patients with multiple myeloma byKathleen Lau June 17, 2021 0
#VisualAbstract Reduced-dose lenalidomide regimen significantly prolongs event-free survival in elderly, intermediate-fit patients with newly diagnosed multiple myeloma byKathleen Lau June 11, 2021 0
#VisualAbstract Phase 2 trial shows umbralisib is safe and effective in patients with chronic lymphocytic leukemia who are intolerant to BTK or PI3Kδ inhibitor therapy byKathleen Lau June 4, 2021 0
#VisualAbstract Phase 3 trial shows adding clarithromycin to standard therapy does not improve progression-free survival in patients with multiple myeloma ineligible for autologous transplant byKathleen Lau May 28, 2021 0
#VisualAbstract Phase 1 trial shows loncastuximab tesirine demonstrated significant response rates and an acceptable safety profile in patients with relapsed/refractory B-cell non-Hodgkin lymphoma byKathleen Lau May 21, 2021 0
